What is the 13F Pro Quality Score for ALEC?

13F Pro ranks Alector, Inc. (ALEC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALEC's current score at https://13fpro.ai/research/ALEC (free sign-up required for the full ranking).

Where does 13F Pro source ALEC data?

All Alector, Inc. fundamentals and ownership data come directly from SEC EDGAR. Alector, Inc. files with the SEC under CIK 1653087. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALEC in?

Alector, Inc. (ALEC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALEC research updated on 13F Pro?

ALEC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Alector, Inc.(ALEC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1653087 ALEC stock profile & AI dashboard →

13F Pro Quality Score

8.9/100

Rank #2,820 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

1.1/100

Profitability

4.6/100

Balance Sheet

4.1/100

Earnings Quality

30.0/100

Free Cash Flow

3.6/100

Institutional Flow

68.5/100

Revenue Scale

10.5/100

Dilution Risk

2.6/100

ALEC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Alector, Inc. (ALEC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALEC at 8.9/100 on a 32-signal composite quality model, placing it at rank #2,820 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (1.1) and free cash flow (3.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Alector, Inc. reports quarterly revenue of $1.0M, net income of $-22.9M, free cash flow of $-49.9M. Top institutional holders of ALEC by reported 13-F value include TCG Crossover Management,, BlackRock,, Foresite Capital Management IV,, based on the most recent SEC filings. ALEC trades on the Nasdaq exchange and files with the SEC under CIK 1653087. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALEC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alector, Inc. directly from SEC EDGAR. Alector, Inc.'s 13F Pro composite quality score has ranged between 6 and 72 since 2021, currently 8.9 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Alector, Inc.

Quirks, history, and lore behind ALEC — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in South San Francisco, the heart of biotech country.
2
The Numbers
Like most clinical-stage biotechs, it carries little to no product revenue and burns cash on R&D — its pipeline is the balance sheet, and hope is the business model.
3
The History
Founded in 2013, the company was built around a bold hypothesis: that the immune system — not just neurons — is the key to unlocking treatments for neurodegenerative diseases.
4
The Secret
Its entire scientific identity is built on a field called immuno-neurology — using the brain's own immune cells (microglia) as the therapeutic lever against diseases like Alzheimer's and FTD.
5
The Lore
It landed a major collaboration deal with GlaxoSmithKline worth up to hundreds of millions, giving a small biotech rare big-pharma validation for its microglial approach.
6
The Giveaway
Its ticker is a nod to its name, its science targets Alzheimer's and frontotemporal dementia via the immune system, and its name sounds like it's got a brain — and an 'elector' hidden inside it.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$1.0M

Net Income

Q1 2026

$-22.9M

Free Cash Flow

Q1 2026

$-49.9M

D/E Ratio

Q1 2026

0.94

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+3.6% YoY

$100.6MFY 2024

FY20 $21.1MFY21 $207.1MFY23 $97.1MFY24 $100.6M

Net Income

+8.5% YoY

$-119.0MFY 2024

FY20 $-190.2MFY21 $-36.3MFY23 $-130.0MFY24 $-119.0M

Operating Income

+4.4% YoY

$-145.0MFY 2024

FY20 $-195.2MFY21 $-37.4MFY23 $-151.7MFY24 $-145.0M

EPS (Diluted)

+21.2% YoY

$-1.23FY 2024

FY20 $-2.45FY21 $-0.45FY23 $-1.56FY24 $-1.23

Total Assets

-24.7% YoY

$468.3MFY 2024

FY20 $488.3MFY21 $814.7MFY23 $621.8MFY24 $468.3M

Total Debt

$10.0MFY 2024

FY20 —FY21 —FY23 $0.00FY24 $10.0M

Op. Cash Flow

-24.8% YoY

$-229.9MFY 2024

FY20 $-166.7MFY21 $298.6MFY23 $-184.2MFY24 $-229.9M

Metric	FY 2024	FY 2023	FY 2021	FY 2020	FY 2017	FY 2016
Revenue	$100.6M +3.6%	$97.1M -53.1%	$207.1M +881.5%	$21.1M +464.9%	$3.7M	—
Net Income	$-119.0M +8.5%	$-130.0M -257.8%	$-36.3M +80.9%	$-190.2M -485.7%	$-32.5M	—
Operating Income	$-145.0M +4.4%	$-151.7M -306.2%	$-37.4M +80.9%	$-195.2M -497.2%	$-32.7M	—
EPS (Diluted)	$-1.23 +21.2%	$-1.56 -246.7%	$-0.45 +81.6%	$-2.45	—	—
Total Assets	$468.3M -24.7%	$621.8M -23.7%	$814.7M +66.9%	$488.3M	—	—
Total Debt	$10.0M	$0.00	—	—	—	—
Operating Cash Flow	$-229.9M -24.8%	$-184.2M -161.7%	$298.6M +279.1%	$-166.7M -838.2%	$-17.8M	—

AI Insight: ALEC Financial Trends

Alector is in terminal cash burn with equity collapsing to $10M—the company has months of runway remaining.

• Revenue collapsed from $54M in Q4 2024 to $1M in Q1 2026, a 98% decline over four quarters.

• Operating cash outflow has averaged $49M per quarter since Q2 2025, depleting equity from $127M to $10M.

• Net losses persist every quarter, ranging $23M–$42M, with no path to profitability evident.

⚠ Equity stands at $10M in Q1 2026 against $10M debt—balance sheet is critically stressed.

⚠ At current $50M quarterly cash burn, estimated runway is weeks without material revenue or capital raise.

AI Insight: ALEC Ratio Trends

Alector is unprofitable across all metrics with deteriorating leverage; D/E nearly doubled from Q4 2025 to Q1 2026 TTM.

• ROA worsened from -1.8% in Q4 2024 to -38.2% in Q1 2026, reflecting persistent operating losses and shrinking asset productivity.

• Debt-to-equity jumped from 0.08 in Q4 2024 to 0.94 in TTM 2026, signaling rapid leverage accumulation amid ongoing cash burn.

• Q4 2024 alone showed OpMargin of -13.4% and ROIC of -21.2%; insufficient quarterly data thereafter prevents trend confirmation.

⚠ D/E tripled in final quarter (Q4 2025 0.34 → Q1 2026 TTM 0.94); monitor debt covenant compliance and liquidity runway.

⚠ Sequential ROA deterioration Q4 2024 (-1.8%) to Q1 2026 (-38.2%) suggests accelerating losses; path to profitability unclear.

Get alerted when ALEC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Alector, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALEC

TCG Crossover Management, LLC
$21.5M10,000,000 sh
BlackRock, Inc.
$16.6M7,741,245 sh
Foresite Capital Management IV, LLC
$8.4M3,887,200 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.9M3,678,722 sh
Merck & Co., Inc.
$7.6M3,545,719 sh
D. E. Shaw & Co., Inc.
$7.2M3,332,835 sh
683 Capital Management, LLC
$6.9M3,200,000 sh
BALYASNY ASSET MANAGEMENT L.P.
$6.3M2,935,253 sh
Nantahala Capital Management, LLC
$6.1M2,815,983 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$5.6M2,583,542 sh

Fund	Value	Shares
TCG Crossover Management, LLC	$21.5M	10,000,000
BlackRock, Inc.	$16.6M	7,741,245
Foresite Capital Management IV, LLC	$8.4M	3,887,200
VANGUARD CAPITAL MANAGEMENT LLC	$7.9M	3,678,722
Merck & Co., Inc.	$7.6M	3,545,719
D. E. Shaw & Co., Inc.	$7.2M	3,332,835
683 Capital Management, LLC	$6.9M	3,200,000
BALYASNY ASSET MANAGEMENT L.P.	$6.3M	2,935,253
Nantahala Capital Management, LLC	$6.1M	2,815,983
VANGUARD PORTFOLIO MANAGEMENT LLC	$5.6M	2,583,542

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALEC on your watchlist

Track score changes the day Alector, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALEC a good stock to buy?

13F Pro's AI-powered analysis of Alector, Inc. (ALEC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALEC are available on the ALEC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ALEC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALEC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alector, Inc.'s investment landscape.